Mercy Internal Medicine Service, Trinity Health of New England, Springfield, Massachusetts, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
J Gastroenterol Hepatol. 2023 Nov;38(11):1971-1979. doi: 10.1111/jgh.16318. Epub 2023 Aug 15.
We aim to systematically investigate gastrointestinal (GI) hospitalizations in the United States during the early phase of the COVID-19 pandemic on a national level and the consequence that may inform practice and policies.
A retrospective cross-sectional analysis of adult hospitalizations with GI-related diagnoses or procedures in the United States in 2020 was used, with hospitalizations from 2016 to 2019 used for contextual information.
Hospitalizations with principal and secondary GI diagnoses decreased by 13.3% and 8.2% from 2019 to 2020, respectively. Most GI diagnoses decreased in 2020, with a few exceptions including alcoholic liver disease (increased by 7.8% as a principal diagnosis) and acute liver failure (increased by 11.6% as a secondary diagnosis). The mortality rate of hospitalizations with GI disease increased in 2020 compared with 2019 (for principal diagnosis: adjusted odds ratio 1.08, 95% confidence interval 1.03-1.13, P = 0.001; for secondary diagnosis: adjusted odds ratio 1.10, 95% confidence interval 1.07-1.13, P < 0.001). Most GI procedures decreased except for a notable 8.3% increase in gastrostomy. The per-GI-hospitalization rate of procedures increased for hospitalizations with a principal GI diagnosis (56.4% vs 55.6%, P = 0.003) or unchanged for hospitalizations with secondary GI diagnoses (18.3% vs 18.2%, P = 0.512).
The COVID-19 pandemic resulted in a decrease in the volume of GI hospitalizations and procedures in 2020, but there was an increase in the mortality rate and some specific diagnoses including alcoholic liver disease and acute liver failure. These findings will likely enlighten future research and healthcare resource allocation for GI diseases.
本研究旨在系统性地调查美国在 COVID-19 大流行早期阶段的胃肠(GI)住院情况,并评估其对临床实践和政策的影响。
本研究采用回顾性病例交叉分析方法,纳入美国 2020 年有 GI 相关诊断或治疗的成年患者住院数据,并使用 2016 年至 2019 年的数据作为背景信息。
2020 年,主要和次要 GI 诊断的住院人数分别下降了 13.3%和 8.2%。大多数 GI 诊断在 2020 年均有所减少,只有少数例外,包括酒精性肝病(作为主要诊断增加了 7.8%)和急性肝衰竭(作为次要诊断增加了 11.6%)。与 2019 年相比,2020 年 GI 疾病相关住院的死亡率增加(主要诊断:校正比值比 1.08,95%置信区间 1.03-1.13,P=0.001;次要诊断:校正比值比 1.10,95%置信区间 1.07-1.13,P<0.001)。除胃造口术显著增加 8.3%外,大多数 GI 手术均减少。主要 GI 诊断的住院患者的每例 GI 治疗住院率增加(56.4%比 55.6%,P=0.003),而次要 GI 诊断的住院患者的每例 GI 治疗住院率无变化(18.3%比 18.2%,P=0.512)。
COVID-19 大流行导致 2020 年 GI 住院和治疗的数量减少,但死亡率和某些特定诊断(包括酒精性肝病和急性肝衰竭)增加。这些发现可能为未来的 GI 疾病研究和医疗资源配置提供启示。